Clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis—Sionna Therapeutics (SION) priced its upsized initial public offering of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback